Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398301 | 1.00 | LOXL2 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488027 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488414 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2488024 | 0.99 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL30457900 | 0.77 | TAS1R3 (0.50) | LOXL2AGXTPSMB5PSMB8TAS1R3 | |
| SCHEMBL4436085 | 0.76 | CYP2D6 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL4340930 | 0.76 | CYP2D6 (0.44) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL19550896 | 0.74 | LOXL2 (0.43) | LOXL2CYP2D6HIF1AMAOAMAOB | |
| SCHEMBL30458044 | 0.74 | SIGMAR1 (0.49) | LOXL2CYP2D6HIF1AMAOBSIGMAR1 | |
| SCHEMBL30457823 | 0.74 | SIGMAR1 (0.49) | LOXL2CYP2D6HIF1AMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226852-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | claimed |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | claimed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | claimed |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525916-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | Bexson Biomedical, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250051778-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-02-13 | — | — | US | disclosed |
| EP-1905760-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | FUJIMOTO CO LTD (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20100324300-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE | YONEDA FUMIO | 2010-12-23 | — | — | US | disclosed |
| US-7807840-B2 | Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate | FUJIMOTO CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| EP-2086331-A2 | METHODS OF TREATING NEURONAL DISORDERS USING MNTF PEPTIDES AND ANALOGS THEREOF | Genervon Biopharmaceuticals LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090124813-A1 | Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate | FUJIMOTO CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090048162-A1 | METHODS OF TREATING NEURONAL DISORDERS USING MNTF PEPTIDES AND ANALOGS THEREOF | GENERVON BIOPHARMACEUTICALS LLC (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008057609-A2 | METHODS OF TREATING NEURONAL DISORDERS USING MNTF PEPTIDES AND ANALOGS THEREOF | GENERVON BIOPHARMACEUTICALS LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1905760-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | Fujimoto Co., Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
| JP-2003089643-A | APOPTOSIS SUPPRESSING AGENT | FUJIMOTO CORPORATION:KK | 2003-03-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124813-A1 | Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate | API5, CASP5, BAD | LOXL2 3348/4885CYP2D6 232/4885HIF1A 3419/4885 |
| US-20260014191-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A4, SLC6A3, SIGMAR1 | LOXL2 4310/4885CYP2D6 25/4885HIF1A 4630/4885 |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | TMSB10, PNMT, HNMT | LOXL2 4402/4885CYP2D6 3599/4885HIF1A 692/4885 |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | TMSB10, PNMT, HNMT | LOXL2 4454/4885CYP2D6 3495/4885HIF1A 646/4885 |
| US-20260027148-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC6A3, SIGMAR1, SLC6A4 | LOXL2 4379/4885CYP2D6 29/4885HIF1A 4611/4885 |
| US-20100324300-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE | API5, CASP5, BAD | LOXL2 3348/4885CYP2D6 232/4885HIF1A 3419/4885 |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | MC2R, SLC26A3, SLC5A1 | LOXL2 3319/4885CYP2D6 1426/4885HIF1A 4577/4885 |
| US-12472201-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | LOXL2 3607/4885CYP2D6 1358/4885HIF1A 4621/4885 |
| US-20260014190-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SIGMAR1, OPRK1, SLC6A2 | LOXL2 3606/4885CYP2D6 26/4885HIF1A 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.